RxDoctor Payments Data

William Brawner, MD

Ophthalmology · Tupelo, MSNPI 1053302125

Payments from drug & device makers

$2,015in general payments, 2019–2025

Across 41 payments — averaging $49.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$933
  • Inspire Medical Systems, Inc.$212
  • Bausch & Lomb Americas Inc.$171
  • Glaukos Corporation$149
  • Mallinckrodt Hospital Products Inc.$136
  • AbbVie$124
  • plus $291 from 6 others

What the payments were for

  • Food & beverage$2,015100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,015 in reported general payments places this provider in the 50th percentile of 150 ophthalmology providers in Mississippi.

See all ophthalmology providers in Mississippi

Medicare billing

Part B allowed, 2024
$387,811
Medicare patients
1,488
Services billed
3,887

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine21$22,466
CombiganBrimonidine Tartrate/Timolol18$5,338
Latanoprost597$4,554
Travoprost12$3,707
Timolol Maleate214$3,548
Brinzolamide11$2,540
Prednisolone Acetate53$1,928
Dorzolamide Hcl96$1,734
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat158$1,710
Cromolyn Sodium46$781
Brimonidine Tartrate85$769
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha90$694
Doxycycline Hyclate16$403
Ketorolac Tromethamine18$273
Ciprofloxacin Hcl17$271

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Combigan$124$27,80439 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 150 ophthalmology providers in Mississippi.

Other ophthalmology in Tupelo

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →